Keyword: Ono Pharmaceutical
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the drugmaker is back with another green light.
Merck will pony up $625 million plus royalties on its blockbuster cancer med Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers. The royalty stream could be "quite meaningful," one analyst said.
A top BIO official said a sudden change of rules in Japan will make the country “less predictable and more risky for innovators” going forward.
Officials in Japan have slashed in half the price of Bristol-Myers Squibb's Opdivo in the country, more than a year ahead of the med’s regularly scheduled price review.
The PD-1 inhibitor patent battle raging between Merck and Bristol-Myers Squibb in the U.S., Europe and Australia has now reached Japan.
Pressure is building in Japan for an out-of-cycle reduction in the price of Ono's cancer drug Opdivo.